Nebenwirkungen · Altuvoct
ALTUVOCT 250 IU powder and solvent for solution for injection ALTUVOCT 500 IU powder and solvent for solution for injection ALTUVOCT 750 IU powder and solvent for solution for injection ALTUVOCT 1 000 IU powder and solvent for solution for injection ALTUVOCT 2 000 IU powder and solvent for solution for injection ALTUVOCT 3 000 IU powder and solvent for solution for injection ALTUVOCT 4 000 IU powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 7
HOS-150441 · Präparat HOS-100320
Table 2 presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level). Frequencies of adverse reactions are based on Phase 3 clinical studies in 277 previously treated patients (PTPs) with severe haemophilia A, of which 161 (58.2%) were adults (18 years of age and older), 37 (13.4%) were adolescents (12 to < 18 years of age), and 79 (28.5%) were children under the age of 12 years.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-12T10:39:56Z · SHA-256 5d7e3537978f52e0d1e648973f5eac8f2f1dffeef273f449a29fb6f7195d3284 · Passage 86c1aba94ee0c3fd3626142b879a9eeada21e431cb080419a8756618956da0e4 · Zeichen 797–1220 im Abschnitt